PVEN Stock Overview
Press Ventures, Inc. owns rights to the cedar leaf oil diffusion (CLO-D) technology in Poland.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Press Ventures, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | 0% |
3 Year Change | -99.67% |
5 Year Change | -99.00% |
Change since IPO | -99.94% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
PVEN | US Household Products | US Market | |
---|---|---|---|
7D | 0% | -0.6% | 0.6% |
1Y | 0% | 10.3% | 29.5% |
Return vs Industry: PVEN underperformed the US Household Products industry which returned 10.5% over the past year.
Return vs Market: PVEN underperformed the US Market which returned 29.8% over the past year.
Price Volatility
PVEN volatility | |
---|---|
PVEN Average Weekly Movement | n/a |
Household Products Industry Average Movement | 2.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PVEN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PVEN's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Edward Denkiewicz |
Press Ventures, Inc. owns rights to the cedar leaf oil diffusion (CLO-D) technology in Poland. The patented CLO-D technology converts the cedar leaf oil into a vapor, and enables the diffusion of vapors for the killing of bacteria, mold, and viruses, such as Anthrax and the H1N1 virus in buildings. It focuses to distribute its products through a network of air conditioning installation companies.
Press Ventures, Inc. Fundamentals Summary
PVEN fundamental statistics | |
---|---|
Market cap | US$315.00 |
Earnings (TTM) | -US$41.16k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PVEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PVEN income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$41.16k |
Earnings | -US$41.16k |
Last Reported Earnings
Jul 31, 2013
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did PVEN perform over the long term?
See historical performance and comparison